Revolution Medicines to Participate in Upcoming Investor Conferences

November 9, 2022

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the 5th Annual Evercore ISI HealthCONx Conference.

Details of these events are as follows:

- **H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference**
  Conference Date: November 14, 2022
  Fireside Chat Time/Date: 7:00 a.m. Eastern on Monday, November 14, 2022
  Format: Virtual conference; webcast available

- **5th Annual Evercore ISI HealthCONx Conference**
  Conference Date: November 29 – December 1, 2022
  Fireside Chat Time/Date: 2:15 p.m. Eastern on Thursday, December 1, 2022
  Format: Virtual conference; webcast available

Webcasts of the H.C. Wainwright and Evercore ISI fireside chats can be accessed at: https://ir.revmed.com/events-and-presentations. Archived replays of the webcasts will be available on the investors section of the company's website for at least 14 days following the events.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RAS ^{MULTI}) and RMC-6291(KRAS^{G12C}) are currently in clinical development. Additional RAS(ON) Inhibitors in the company's pipeline include RMC-9805 (KRAS ^{G12D}), currently in IND-enabling development, RMC-8839 (KRAS^{G13C}), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com